India
· Delayed Price · Currency is INR Gland Pharma Statistics
Total Valuation
Gland Pharma has a market cap or net worth of INR 261.73 billion. The enterprise value is 234.37 billion.
| Market Cap | 261.73B |
| Enterprise Value | 234.37B |
Important Dates
The last earnings date was Tuesday, May 20, 2025.
| Earnings Date | May 20, 2025 |
| Ex-Dividend Date | Aug 14, 2025 |
Share Statistics
| Current Share Class | 164.76M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 73.18M |
Valuation Ratios
The trailing PE ratio is 37.47 and the forward PE ratio is 27.84.
| PE Ratio | 37.47 |
| Forward PE | 27.84 |
| PS Ratio | 4.66 |
| PB Ratio | 2.86 |
| P/TBV Ratio | 2.98 |
| P/FCF Ratio | 49.37 |
| P/OCF Ratio | 28.61 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.47, with an EV/FCF ratio of 44.21.
| EV / Earnings | 33.55 |
| EV / Sales | 4.17 |
| EV / EBITDA | 18.47 |
| EV / EBIT | 26.30 |
| EV / FCF | 44.21 |
Financial Position
The company has a current ratio of 4.33, with a Debt / Equity ratio of 0.03.
| Current Ratio | 4.33 |
| Quick Ratio | 2.92 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.25 |
| Debt / FCF | 0.59 |
| Interest Coverage | 21.22 |
Financial Efficiency
Return on equity (ROE) is 7.82% and return on invested capital (ROIC) is 6.00%.
| Return on Equity (ROE) | 7.82% |
| Return on Assets (ROA) | 5.09% |
| Return on Invested Capital (ROIC) | 6.00% |
| Return on Capital Employed (ROCE) | 9.22% |
| Revenue Per Employee | 13.10M |
| Profits Per Employee | 1.63M |
| Employee Count | 4,286 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 1.36 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.87% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -12.87% |
| 50-Day Moving Average | 1,492.55 |
| 200-Day Moving Average | 1,669.23 |
| Relative Strength Index (RSI) | 67.68 |
| Average Volume (20 Days) | 9,310 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Gland Pharma had revenue of INR 56.17 billion and earned 6.99 billion in profits. Earnings per share was 42.40.
| Revenue | 56.17B |
| Gross Profit | 33.27B |
| Operating Income | 8.91B |
| Pretax Income | 10.63B |
| Net Income | 6.99B |
| EBITDA | 12.69B |
| EBIT | 8.91B |
| Earnings Per Share (EPS) | 42.40 |
Balance Sheet
The company has 30.50 billion in cash and 3.14 billion in debt, giving a net cash position of 27.36 billion.
| Cash & Cash Equivalents | 30.50B |
| Total Debt | 3.14B |
| Net Cash | 27.36B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 91.51B |
| Book Value Per Share | 555.30 |
| Working Capital | 52.18B |
Cash Flow
In the last 12 months, operating cash flow was 9.15 billion and capital expenditures -3.85 billion, giving a free cash flow of 5.30 billion.
| Operating Cash Flow | 9.15B |
| Capital Expenditures | -3.85B |
| Free Cash Flow | 5.30B |
| FCF Per Share | n/a |
Margins
Gross margin is 59.24%, with operating and profit margins of 15.86% and 12.44%.
| Gross Margin | 59.24% |
| Operating Margin | 15.86% |
| Pretax Margin | 18.92% |
| Profit Margin | 12.44% |
| EBITDA Margin | 22.59% |
| EBIT Margin | 15.86% |
| FCF Margin | 9.44% |
Dividends & Yields
This stock pays an annual dividend of 18.00, which amounts to a dividend yield of 1.18%.
| Dividend Per Share | 18.00 |
| Dividend Yield | 1.18% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 47.17% |
| Buyback Yield | -0.01% |
| Shareholder Yield | 1.17% |
| Earnings Yield | 2.67% |
| FCF Yield | 2.03% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |